IL23A and rheumatoid arthritis: In the future, we will continue to refine related research, elucidate the structure-activity relationships between XTS and key IL-23/IL-17 proteins using surface plasmon resonance (SPR) and molecular docking techniques, conduct long-term toxicity tests and reproductive toxicity screening in accordance with GLP standards, and conduct comprehensive studies on anti-RA effects in other RA animal models or organoid models, with the aim of providing more comprehensive and scientific evidence for the clinical application of XTS.